Please login to the form below

Not currently logged in
Email:
Password:

methylphenidate

This page shows the latest methylphenidate news and features for those working in and with pharma, biotech and healthcare.

UCB's $1.53bn generics sale falls through

UCB's $1.53bn generics sale falls through

formulation of methylphenidate hydrochloride for attention-deficit hyperactivity disorder (ADHD). ... While we are working on clarifying the situation around methylphenidate ER we will continue the divestiture process for Kremers Urban," said UCB chief

Latest news

  • J&J earnings leap on buoyant pharma sales J&J earnings leap on buoyant pharma sales

    On the downside, generic competition continued to take its toll on older drugs such as gastrointestinal Aciphex/Pariet (rabeprazole) and attention-deficit hyperactivity disorder drug Concerta (methylphenidate).

  • Buoyant pharma sales drive J&J's Q3 results Buoyant pharma sales drive J&J's Q3 results

    On the downside, attention-deficit hyperactivity disorder (ADHD) treatment Concerta (methylphenidate) continued to succumb to generic competition, losing $110m in sales compared to the third quarter of 2012 to come in

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    In the absence of Adderall XR, the price of rival ADHD brand Concerta (methylphenidate) from Johnson &Johnson would be around 5 per cent higher - at $101 per month instead of

  • Think positive: the rise of 'smart drugs' Think positive: the rise of 'smart drugs'

    which are reported with both methylphenidate and modafinil, says Mehta, who freely admits this hypothesis is untested. “ ... And with decades of experience with methylphenidate and modafinil there does not seem to be any major health issues surrounding

  • OTC recovery helps J&J in first-quarter OTC recovery helps J&J in first-quarter

    On the downside, attention-deficit hyperactivity disorder (ADHD) product Concerta (methylphenidate) and gastrointestinal drug Aciphex/Pariet (rabeprazole) continued to be affected by generic competition.

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

  • Pharma deals during October 2012 Pharma deals during October 2012

    Established products – new formulations. Pfizer's acquisition of NextWave Pharmaceuticals bolsters its established products business unit bringing Quillivant XR (methylphenidate hydrochloride), which recently secured FDA approval for attention

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics